Sickle cell disease trials recruiting in Illinois

All Sickle cell disease trials nationally

Cities in Illinois

Recruiting trials in Illinois

• A Phase 1b, Open-Label Study of DISC-3405 in Participants With Sickle Cell Disease (SCD)
  NCT07187973 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Illinois: Chicago
• A Phase 2/3 Study of Osivelotor in Adult and Adolescent Participants With SCD
  NCT05431088 · Phase: Phase 2, Phase 3 · Ages: 12 Years and older · Sex: All (male and female) · Illinois: Chicago
• A Research Study Looking at Long-term Treatment With Etavopivat in People With Sickle Cell Disease or Thalassaemia
  NCT06609226 · Phase: Phase 3 · Ages: 2 Years and older · Sex: All (male and female) · Illinois: Chicago
• A Study of Nicotinamide With Oral Tetrahydrouridine and Decitabine to Treat High Risk Sickle Cell Disease
  NCT04055818 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Illinois: Chicago
• A Study to Evaluate BMS-986470 in Healthy Volunteers and Participants With Sickle Cell Disease
  NCT06481306 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Illinois: Chicago
• A Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease
  NCT06612268 · Phase: Phase 3 · Ages: 12 Years and older · Sex: All (male and female) · Illinois: Chicago
• A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)
  NCT06439082 · Phase: Phase 3 · Ages: 12 Years to 100 Years · Sex: All (male and female) · Illinois: Chicago
• ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders
  NCT04398628 · Phase: Not specified · Ages: No age limits stated · Sex: All (male and female) · Illinois: Chicago, Peoria
• Comparing the Effectiveness of Matched Related Donor Hematopoietic Stem Cell Transplantation to Disease Modifying Therapy in Pediatric Patients With Sickle Cell Disease
  NCT06941389 · Phase: Not specified · Ages: 3 Years to 20 Years · Sex: All (male and female) · Illinois: Chicago
• Delivering Patient-Facing Evidence-Based Guidelines Through mHealth to Adults With Sickle Cell Disease
  NCT06919224 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · Illinois: Chicago
• Mindfulness-Based Intervention for Pain and Sleep in Adolescents and Young Adults With Sickle Cell Disease
  NCT07402811 · Phase: Not applicable (e.g. observational or device study) · Ages: 15 Years to 39 Years · Sex: All (male and female) · Illinois: Chicago
• Minimizing Toxicity in HLA-identical Sibling Donor Transplantation for Children With Sickle Cell Disease
  NCT03587272 · Phase: Phase 2 · Ages: 2 Years to 25 Years · Sex: All (male and female) · Illinois: Chicago
• Peer Support for Adolescents and Emerging Adults With Sickle Cell Pain
  NCT06374238 · Phase: Not applicable (e.g. observational or device study) · Ages: 16 Years to 30 Years · Sex: All (male and female) · Illinois: Chicago
• Recruitment and Engagement in Care to Impact Practice Enhancement (RECIPE) for Sickle Cell Disease
  NCT06385886 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · Illinois: Chicago
• Safety, Efficacy, and Pharmacokinetics of CSL889 in Adults and Adolescents With Sickle Cell Disease During Vaso-Occlusive Crisis
  NCT06699849 · Phase: Phase 2 · Ages: 12 Years and older · Sex: All (male and female) · Illinois: Chicago
• Sickle Cell Clinical Research and Intervention Program
  NCT02098863 · Phase: Not specified · Ages: No age limits stated · Sex: All (male and female) · Illinois: Peoria
• Study of HLA-Haploidentical Stem Cell Transplantation to Treat Clinically Aggressive Sickle Cell Disease
  NCT03121001 · Phase: Phase 2 · Ages: 16 Years to 60 Years · Sex: All (male and female) · Illinois: Chicago
• Targeting the Pathophysiology of Sickle Cell-Related Kidney Disease Using the SGLT2 Inhibitors, Empagliflozin
  NCT07175051 · Phase: Phase 2 · Ages: 18 Years to 60 Years · Sex: All (male and female) · Illinois: Chicago
• The Efficacy and Safety of Rilzabrutinib in Participants Aged 10 to 65 Years With Sickle-cell Disease
  NCT06975865 · Phase: Phase 3 · Ages: 10 Years to 65 Years · Sex: All (male and female) · Illinois: Chicago
• Tocilizumab for Acute Chest Syndrome
  NCT05640271 · Phase: Phase 2 · Ages: 12 Years and older · Sex: All (male and female) · Illinois: Chicago